STOCKHOLM, Oct. 30, 2019 /PRNewswire/ -- Medivir AB
(Nasdaq Stockholm: MVIR) today announces that a poster
entitled "MIV-818 stimulates an anti-tumor immune response in vitro
and enhances the effects of pembrolizumab" was presented at the
AACR-NCI-EORTC conference in Boston. The data shows that MIV-818 exerts
favorable immunomodulating effects in vitro by increasing immune
cytokine levels in complex tumor microenvironment models, and the
white blood cell mediated killing of cancer cells. These effects
are further enhanced in combination with the anti-PD1 check-point
inhibitor pembrolizumab.
"It is exciting that MIV-818, in addition to directly targeting
cancer cells, also modulates the anti-tumor immune-response. This
opens the possibility for potential future combinations with
immunotherapy" - says Dr Fredrik Öberg, CSO.
For further information, please contact:
Dr
Uli Hacksell
CEO
Medivir AB
phone: +46(0)8-5468-3100.
About MIV-818
MIV-818 is a pro-drug designed to selectively treat liver
cancers and to minimize side effects. It has the potential to
become the first liver-targeted, orally administered drug to
benefit patients with HCC and other forms of liver cancer. A phase
I study in patients with liver cancer is ongoing.
About liver cancer
Liver cancer is the third leading cause of cancer-related deaths
worldwide and hepatocellular carcinoma (HCC) is the most common
cancer that arises in the liver. Although existing therapies for
advanced HCC are capable of extending the lives of patients,
treatment benefits are low while death rates remain high. HCC is a
very diverse disease with multiple cancer cell types and without
specific mutations seen in other tumor types. This has contributed
to the lack of success of molecularly targeted agents in HCC. The
limited overall benefit, taken together with the poor overall
prognosis for patients with intermediate and advanced HCC, results
in a large unmet medical need.
About Medivir
Medivir develops innovative drugs with a focus on cancer where
the unmet medical needs are high. The company is investing in
indication areas where available therapies are limited or missing
and there are great opportunities to offer significant improvements
to patients. Collaborations and partnerships are important parts of
Medivir's business model and the drug development as well as the
commercialization is conducted either by Medivir or in partnership.
Medivir's share (ticker: MVIR) is listed on Nasdaq Stockholm's
Small Cap list. www.medivir.com.
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/medivir/r/medivir-presents-miv-818-data-at-aacr-nci-eortc-in-boston,c2949312
The following files are available for download:
|
https://mb.cision.com/Main/652/2949312/1132536.pdf
|
Press release
(PDF)
|
View original
content:http://www.prnewswire.com/news-releases/medivir-presents-miv-818-data-at-aacr-nci-eortc-in-boston-300947953.html
SOURCE Medivir
